As a research assistant professor in the laboratory of Dr. John Crispino, I lead a major effort to develop novel therapies for patients with blood cancers, I assist other lab members in their translational initiatives, and I collaborate with external colleagues to enhance their cancer research. The main area of my research involves the investigation of the pathogenesis of acute megakaryocytic leukemia (AMKL), and the role of megakaryocytes in the development of other blood cancers, such as primary myelofibrosis (PMF), which is a subtype of the myeloproliferative neoplasms (MPNs). During normal development, megakaryocytes progress through repeated rounds of the cell cycle without cell division to become polyploid. I hypothesized that small molecules that could force malignant megakaryocytes to become polyploid and differentiate would act as anti- tumor agents. Indeed, I discovered that megakaryocytic polyploidy inducing molecules such as dimethylfasudil and MLN8237 (Alisertib), which inhibit Aurora A kinase, have potent anti-AMKL activity in vitro and in vivo. Moreover, these compounds showed strong anti-tumor activity in patient samples and mouse models of PMF. These findings lead to the opening of a Phase 1 clinical trial of Alisertib in patients with AMKL or PMF. From this study I accumulated an enormous amount of experience in drug development from the design of high throughput small molecule and RNAi screens to preclinical studies with animal models. Over the next five years, I will leverage my experience to further my own research as well as to aid lab colleagues in their studies to find new therapies for hematologic malignancies. My work can be divided into four focus areas: A) development of therapies for megakaryocytic malignancies; B) validation of PAK1 as a target in the MPNs; C) development of DYRK1A inhibitors for AMKL and B-ALL; D) investigation of novel therapies to target cohesin mutations in AMKL and AML. I look forward to continuing to be an instrumental leader in Dr. Crispino's lab, to collaborating with other NCI-funded investigators, and to bringing more novel therapeutics to patients.
My passion is to perform cutting edge research in hematology/oncology with the goal of translating my discoveries into new therapies for patients. I led an international effort to identify drugs that induce the polyploidization of malignant megakaryocytes, which has culminated in the opening of a Phase 1 study of an aurora A kinase inhibitor in acute megakaryocytic leukemia and primary myelofibrosis. Over the next five years I will continue to study megakaryocytic blood cancers as well as support the translational cancer research of colleagues in my laboratory as well as those of external collaborators.
|Yang, Xuejing; Lu, Bin; Sun, Xueqin et al. (2018) ANP32A regulates histone H3 acetylation and promotes leukemogenesis. Leukemia 32:1587-1597|
|Zhao, Baobing; Mei, Yang; Cao, Lan et al. (2018) Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms. J Clin Invest 128:125-140|
|Gilles, Laure; Arslan, Ahmet Dirim; Marinaccio, Christian et al. (2017) Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. J Clin Invest 127:1316-1320|
|Yang, Qiong; Crispino, John D; Wen, Qiang Jeremy (2017) Kinase signaling and targeted therapy for primary myelofibrosis. Exp Hematol 48:32-38|
|Nitulescu, Ioana I; Meyer, Sara C; Wen, Qiang Jeremy et al. (2017) Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation. EBioMedicine 26:112-125|
|Sun, Xueqin; Lu, Bin; Han, Cuijuan et al. (2017) ANP32A dysregulation contributes to abnormal megakaryopoiesis in acute megakaryoblastic leukemia. Blood Cancer J 7:661|
|Yu, Chunjie; Yang, Qiong; Chen, Yuhong et al. (2016) Tyrosine 625 plays a key role and cooperates with tyrosine 630 in MPL W515L-induced signaling and myeloproliferative neoplasms. Cell Biosci 6:34|